Jianhe Li
Changsha, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Reliability and Validity of the Chinese Version of the Parental Acceptance Questionnaire (6-PAQ) Among Parents of Children With or Without Hearing Loss.
Journal: Journal of clinical psychology
Published: May 07, 2024
Efficacy and safety of Chinese patent medicines combined with antidepressants for treatment of depression in adults: A multiple-treatment meta-analysis.
Journal: Journal of psychiatric research
Published: October 13, 2023
Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials.
Journal: Frontiers in pharmacology
Published: September 06, 2022
Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
Journal: BMC health services research
Published: June 08, 2022
Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.
Journal: Frontiers in pharmacology
Published: July 29, 2021
Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
Journal: Frontiers in pharmacology
Published: June 11, 2021
Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Journal: Frontiers in oncology
Published: March 22, 2021
Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China.
Journal: Rheumatology and therapy
Published: March 09, 2021
Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure.
Journal: Rheumatology and therapy
Published: February 11, 2021
First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.
Journal: Clinical therapeutics
Published: June 30, 2020
Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.
Journal: PloS one
Published: May 29, 2019
Last Updated: 09/26/2026